JP4866467B2 - 調節性ｔ細胞エピトープ、組成物およびその使用 - Google Patents

調節性ｔ細胞エピトープ、組成物およびその使用 Download PDF

Info

Publication number
JP4866467B2
JP4866467B2 JP2009548278A JP2009548278A JP4866467B2 JP 4866467 B2 JP4866467 B2 JP 4866467B2 JP 2009548278 A JP2009548278 A JP 2009548278A JP 2009548278 A JP2009548278 A JP 2009548278A JP 4866467 B2 JP4866467 B2 JP 4866467B2
Authority
JP
Japan
Prior art keywords
cells
tregitope
regulatory
cell
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009548278A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010516290A (ja
JP2010516290A5 (enExample
Inventor
グルート アン デ
ウィリアム マルティン
ダン リベラ
Original Assignee
エピバックス インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39674696&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP4866467(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by エピバックス インコーポレーテッド filed Critical エピバックス インコーポレーテッド
Publication of JP2010516290A publication Critical patent/JP2010516290A/ja
Publication of JP2010516290A5 publication Critical patent/JP2010516290A5/ja
Application granted granted Critical
Publication of JP4866467B2 publication Critical patent/JP4866467B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Reproductive Health (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
JP2009548278A 2007-01-30 2008-01-29 調節性ｔ細胞エピトープ、組成物およびその使用 Expired - Fee Related JP4866467B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89834707P 2007-01-30 2007-01-30
US60/898,347 2007-01-30
PCT/US2008/001148 WO2008094538A2 (en) 2007-01-30 2008-01-29 Regulatory t cell epitopes, compositions and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011247226A Division JP5643739B2 (ja) 2007-01-30 2011-11-11 調節性ｔ細胞エピトープ、組成物およびその使用

Publications (3)

Publication Number Publication Date
JP2010516290A JP2010516290A (ja) 2010-05-20
JP2010516290A5 JP2010516290A5 (enExample) 2011-06-16
JP4866467B2 true JP4866467B2 (ja) 2012-02-01

Family

ID=39674696

Family Applications (10)

Application Number Title Priority Date Filing Date
JP2009548278A Expired - Fee Related JP4866467B2 (ja) 2007-01-30 2008-01-29 調節性ｔ細胞エピトープ、組成物およびその使用
JP2011247226A Expired - Fee Related JP5643739B2 (ja) 2007-01-30 2011-11-11 調節性ｔ細胞エピトープ、組成物およびその使用
JP2014154372A Active JP6121369B2 (ja) 2007-01-30 2014-07-30 調節性ｔ細胞エピトープ、組成物およびその使用
JP2017064298A Expired - Fee Related JP6472476B2 (ja) 2007-01-30 2017-03-29 調節性ｔ細胞エピトープ、組成物およびその使用
JP2019008352A Pending JP2019089793A (ja) 2007-01-30 2019-01-22 調節性ｔ細胞エピトープ、組成物およびその使用
JP2021011596A Withdrawn JP2021073255A (ja) 2007-01-30 2021-01-28 調節性ｔ細胞エピトープ、組成物およびその使用
JP2021072446A Pending JP2021107443A (ja) 2007-01-30 2021-04-22 調節性ｔ細胞エピトープ、組成物およびその使用
JP2021072455A Pending JP2021107444A (ja) 2007-01-30 2021-04-22 調節性ｔ細胞エピトープ、組成物およびその使用
JP2022155804A Pending JP2022177270A (ja) 2007-01-30 2022-09-29 調節性ｔ細胞エピトープ、組成物およびその使用
JP2024033497A Pending JP2024059975A (ja) 2007-01-30 2024-03-06 調節性ｔ細胞エピトープ、組成物およびその使用

Family Applications After (9)

Application Number Title Priority Date Filing Date
JP2011247226A Expired - Fee Related JP5643739B2 (ja) 2007-01-30 2011-11-11 調節性ｔ細胞エピトープ、組成物およびその使用
JP2014154372A Active JP6121369B2 (ja) 2007-01-30 2014-07-30 調節性ｔ細胞エピトープ、組成物およびその使用
JP2017064298A Expired - Fee Related JP6472476B2 (ja) 2007-01-30 2017-03-29 調節性ｔ細胞エピトープ、組成物およびその使用
JP2019008352A Pending JP2019089793A (ja) 2007-01-30 2019-01-22 調節性ｔ細胞エピトープ、組成物およびその使用
JP2021011596A Withdrawn JP2021073255A (ja) 2007-01-30 2021-01-28 調節性ｔ細胞エピトープ、組成物およびその使用
JP2021072446A Pending JP2021107443A (ja) 2007-01-30 2021-04-22 調節性ｔ細胞エピトープ、組成物およびその使用
JP2021072455A Pending JP2021107444A (ja) 2007-01-30 2021-04-22 調節性ｔ細胞エピトープ、組成物およびその使用
JP2022155804A Pending JP2022177270A (ja) 2007-01-30 2022-09-29 調節性ｔ細胞エピトープ、組成物およびその使用
JP2024033497A Pending JP2024059975A (ja) 2007-01-30 2024-03-06 調節性ｔ細胞エピトープ、組成物およびその使用

Country Status (11)

Country Link
US (18) US7884184B2 (enExample)
EP (13) EP2423219B1 (enExample)
JP (10) JP4866467B2 (enExample)
KR (3) KR20100014871A (enExample)
CN (4) CN101687912B (enExample)
AT (1) ATE525392T1 (enExample)
AU (1) AU2008211227B2 (enExample)
CA (6) CA2677073C (enExample)
IL (3) IL200129A (enExample)
MX (3) MX347197B (enExample)
WO (1) WO2008094538A2 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008094538A2 (en) 2007-01-30 2008-08-07 Epivax, Inc. Regulatory t cell epitopes, compositions and uses thereof
DE102007030904A1 (de) * 2007-07-03 2009-02-05 Pharis Biotec Gmbh Humanes zirkulierendes antivirales Albumin-Fragment (ALB-408) und seine Verwendung
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP4108671B1 (en) 2010-10-01 2024-11-20 ModernaTX, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
JP6130307B2 (ja) 2011-03-17 2017-05-17 ザ ユニバーシティ オブ バーミンガム 再指向性免疫療法
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
ES2911677T3 (es) 2011-10-03 2022-05-20 Modernatx Inc Nucleósidos, nucleótidos y ácidos nucleicos modificados, y sus usos
CN106986927A (zh) * 2011-12-13 2017-07-28 法国国家科学研究中心 修饰肽及其用于治疗自体免疫疾病的用途
MX2014007233A (es) 2011-12-16 2015-02-04 Moderna Therapeutics Inc Composiciones de nucleosidos, nucleotidos y acidos nucleicos modificados.
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
WO2013151663A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of membrane proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
PT2922554T (pt) 2012-11-26 2022-06-28 Modernatx Inc Arn modificado nas porções terminais
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
WO2015051214A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
EP4052724A1 (en) * 2013-12-06 2022-09-07 The Broad Institute Inc. Formulations for neoplasia vaccines
PT3134131T (pt) 2014-04-23 2022-03-24 Modernatx Inc Vacinas de ácidos nucleicos
WO2016054114A1 (en) 2014-09-29 2016-04-07 The Regents Of The University Of California Compositions for expanding regulatory t cells (treg), and treating autoimmune and inflammatory diseases and conditions
US10213482B2 (en) 2014-12-12 2019-02-26 Immupharma France Sa Methods of treating chronic inflammatory diseases
CN107427590B (zh) 2015-02-02 2021-08-31 伯明翰大学 具有多个t细胞表位的靶向部分肽表位复合物
AU2016258929B2 (en) 2015-05-04 2020-10-08 Epivax, Inc. Modified H7 hemagluttinin glycoprotein of the influenza A/Shanghai/2/2013 H7 sequence
JP2018517405A (ja) * 2015-05-04 2018-07-05 エピバックス インコーポレーテッド インフルエンザａ／上海／２／２０１３ ｈ７配列の改変ｈ７赤血球凝集素糖タンパク質
PL3377103T5 (pl) 2015-11-19 2025-07-07 Revitope Limited Komplementacja funkcjonalnego fragmentu przeciwciała dla dwuskładnikowego układu do przekierowanego zabijania niepożądanych komórek
PL238939B1 (pl) * 2016-11-02 2021-10-18 Instytut Immunologii I Terapii Doświadczalnej Polskiej Akademii Nauk Im Ludwika Hirszfelda We Wrocławiu Peptyd immunosupresyjny i jego zastosowania
WO2019071116A1 (en) * 2017-10-05 2019-04-11 Epivax, Inc. T REGULATORY LYMPHOCYTE EPITOPES
EP3622962A1 (en) * 2018-09-14 2020-03-18 advanceCOR GmbH Short cyclic peptides for the treatment of graves' disease
EP3963335B1 (en) * 2019-05-03 2024-08-21 Epivax Therapeutics, Inc. Neoantigens in cancer
EP4126901A4 (en) * 2020-03-27 2024-04-10 Epivax, Inc. Regulatory t cell epitopes
CA3170819A1 (en) * 2020-03-27 2021-09-30 Biotest Ag Protein comprising at least one regulatory t cell activating epitope
CN111856020B (zh) * 2020-06-19 2022-09-27 南方医科大学南方医院 乙型肝炎病毒（hbv）特异性t细胞检测方法及其应用
US20230321237A1 (en) * 2020-08-13 2023-10-12 Epivax, Inc. Regulatory t cell epitopes
JP2023543801A (ja) * 2020-09-25 2023-10-18 エピバックス、インコーポレイテッド レトロインベルソ制御性ｔ細胞エピトープ
JP2024524730A (ja) * 2021-07-16 2024-07-05 デベヴェ・テクノロジーズ 対象におけるカシュー耐性を増大させるための免疫治療法
WO2024240690A2 (en) 2023-05-19 2024-11-28 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006082406A2 (en) * 2005-02-03 2006-08-10 Antitope Limited Human antibodies and proteins

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
FR2556219B1 (fr) 1983-12-07 1987-06-26 Merieux Inst Nouveau medicament immunomodulateur, a base de fragments fc d'igg humaines
GB8725529D0 (en) † 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US6162432A (en) 1991-10-07 2000-12-19 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
FR2686899B1 (fr) † 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5817308A (en) * 1994-02-14 1998-10-06 University Of Rochester Tolerogenic fusion proteins of immunoglobulins and methods for inducing and maintaining tolerance
DE4425115A1 (de) 1994-07-15 1996-01-18 Boehringer Mannheim Gmbh Verfahren zur Modifizierung der Stabilität von Antikörpern
US5705154A (en) * 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US6254868B1 (en) 1996-03-20 2001-07-03 Immunomedics, Inc. Glycosylated humanized B-cell specific antibodies
US6090381A (en) * 1997-02-11 2000-07-18 Immunomedics, Inc. Stimulation of an immune response with antibodies labeled with the . .alpha-galactosyl epitope
WO1998048837A1 (en) * 1997-04-30 1998-11-05 Enzon, Inc. Polyalkylene oxide-modified single chain polypeptides
US6953675B2 (en) 1997-11-06 2005-10-11 Immunomedics, Inc. Landscaped antibodies and antibody fragments for clinical use
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US6445840B1 (en) 1999-05-28 2002-09-03 Omm, Inc. Micromachined optical switching devices
AU783037B2 (en) 1999-05-28 2005-09-15 Targeted Genetics Corporation Methods and compositions for lowering the level of tumor necrosis factor (TNF) in the TNF-associated disorders
ES2529300T3 (es) † 2000-04-12 2015-02-18 Novozymes Biopharma Dk A/S Proteínas de fusión de albúmina
JP2004502946A (ja) † 2000-07-10 2004-01-29 ゼンコー 改変された免疫原性を有するタンパク質ライブラリーを設計するためのタンパク質設計オートメーション
WO2002074783A2 (en) * 2001-03-15 2002-09-26 Merck Patent Gmbh Modified interferon beta with reduced immunogenicity
US6992174B2 (en) † 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
CN1585778A (zh) * 2001-11-12 2005-02-23 默克专利有限公司 修饰的抗－TNFα抗体
EP1453539B1 (en) † 2001-12-05 2008-11-19 Circassia Limited Immunotherapeutic methods and systems
WO2005077042A2 (en) † 2004-02-09 2005-08-25 Human Genome Sciences, Inc. Albumin fusion proteins
EP1463752A4 (en) † 2001-12-21 2005-07-13 Human Genome Sciences Inc ALBUMIN FUSION PROTEINS
WO2005003296A2 (en) † 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
WO2003060071A2 (en) † 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
WO2003066824A2 (en) † 2002-02-07 2003-08-14 Aventis Behring Gmbh Albumin-fused kunitz domain peptides
US7317091B2 (en) * 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
DK1532262T3 (da) 2002-05-24 2013-09-16 Medtronic Inc Peptidamideringsfremgangsmåde
CA2508375C (en) * 2002-12-02 2014-05-27 Abgenix, Inc. Antibodies directed to tumor necrosis factor and uses thereof
CN1511958A (zh) * 2002-12-31 2004-07-14 王小宁 一种筛选人组织相容性抗原(hla)的t细胞表面抗原肽的体系,及其在制备mhc-抗原肽多聚体中的应用
CA2537055A1 (en) * 2003-08-22 2005-04-21 Medimmune, Inc. Humanization of antibodies
WO2005063815A2 (en) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
US20050142133A1 (en) * 2003-12-03 2005-06-30 Xencor, Inc. Optimized proteins that target the epidermal growth factor receptor
NZ580828A (en) 2004-02-06 2011-09-30 Univ Massachusetts Antibodies against clostridium difficile toxin B and uses thereof
EA010803B1 (ru) * 2004-03-19 2008-12-30 Мерк Патент Гмбх Модифицированные белки буганины, цитотоксины и способы их применения
WO2005097832A2 (en) * 2004-03-31 2005-10-20 Genentech, Inc. Humanized anti-tgf-beta antibodies
AU2005271449A1 (en) 2004-08-03 2006-02-16 The Trustees Of Columbia University In The City Of New York RAGE fusion proteins and methods of use
GEP20105110B (en) 2004-08-03 2010-11-10 Transtech Pharma Inc Rage fusion proteins and their use
CU23504A1 (es) * 2004-09-24 2010-04-13 Ct Ingenieria Genetica Biotech Péptidos y derivados tipo apl de la hsp60 y composiciones farmacéuticas
US7488804B2 (en) † 2005-02-02 2009-02-10 The Regents Of The University Of California Modified fusion molecules for treatment of allergic disease
MX2007015944A (es) 2005-06-20 2008-03-07 Medarex Inc Anticuerpos cd19 y sus usos.
MX2008001865A (es) † 2005-08-12 2008-04-15 Human Genome Sciences Inc Proteinas de fusion de albumina.
CN100349921C (zh) * 2005-11-17 2007-11-21 中国人民解放军第四军医大学 破伤风毒素t细胞表位多肽与人b淋巴细胞刺激因子融合蛋白及其制备
SI1969007T1 (sl) * 2005-12-20 2014-03-31 Bristol-Myers Squibb Company Sestavki in postopki za izdelavo sestavka
JP5374359B2 (ja) * 2006-03-17 2013-12-25 バイオジェン・アイデック・エムエイ・インコーポレイテッド 安定化されたポリペプチド化合物
GB0605735D0 (en) 2006-03-22 2006-05-03 Immunobiology Ltd Composition and method for mediating an immune response
EP2046367A4 (en) † 2006-06-07 2009-11-11 Human Genome Sciences Inc ALBUM INFUSION PROTEINS
AT503861B1 (de) † 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von t-zell-rezeptoren
EP2057465A4 (en) 2006-08-09 2010-04-21 Homestead Clinical Corp ORGANIC PROTEINS AND METHOD OF USE THEREOF
WO2008094538A2 (en) * 2007-01-30 2008-08-07 Epivax, Inc. Regulatory t cell epitopes, compositions and uses thereof
BRPI0812465A2 (pt) 2007-06-08 2014-12-02 Dow Global Technologies Inc Expressão de fragmento de anticorpo solúvel por truncação de domínio ch1

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006082406A2 (en) * 2005-02-03 2006-08-10 Antitope Limited Human antibodies and proteins

Also Published As

Publication number Publication date
US7884184B2 (en) 2011-02-08
ATE525392T1 (de) 2011-10-15
US20180289783A1 (en) 2018-10-11
US20190183993A1 (en) 2019-06-20
CN112279911A (zh) 2021-01-29
KR20100014871A (ko) 2010-02-11
JP2010516290A (ja) 2010-05-20
MX2009008230A (es) 2010-03-08
CA2677073C (en) 2016-03-15
MX2018015933A (es) 2021-11-16
US11045530B2 (en) 2021-06-29
EP2423222B2 (en) 2020-07-29
KR20170037677A (ko) 2017-04-04
US20190030143A1 (en) 2019-01-31
US20180289787A1 (en) 2018-10-11
CA2963138C (en) 2019-05-14
CN107011431B (zh) 2020-11-06
US20180289782A1 (en) 2018-10-11
EP2423220A1 (en) 2012-02-29
EP2125883A2 (en) 2009-12-02
US20110182921A1 (en) 2011-07-28
EP2423219A1 (en) 2012-02-29
EP2450371A1 (en) 2012-05-09
EP2450368A1 (en) 2012-05-09
EP2896630A1 (en) 2015-07-22
US11045531B2 (en) 2021-06-29
JP2019089793A (ja) 2019-06-13
US10751397B2 (en) 2020-08-25
EP2450372A1 (en) 2012-05-09
IL267186B (en) 2020-01-30
CA2963138A1 (en) 2008-08-07
CA3034396C (en) 2022-08-02
EP2423221B1 (en) 2015-04-29
JP2021107444A (ja) 2021-07-29
US20190183994A1 (en) 2019-06-20
CN101687912A (zh) 2010-03-31
AU2008211227A1 (en) 2008-08-07
IL245478A0 (en) 2016-06-30
CN103755789A (zh) 2014-04-30
JP2012087128A (ja) 2012-05-10
KR20140117662A (ko) 2014-10-07
US11045529B2 (en) 2021-06-29
CN103755789B (zh) 2016-12-07
CN107011431A (zh) 2017-08-04
JP2022177270A (ja) 2022-11-30
CA3001783C (en) 2020-09-08
US10925942B2 (en) 2021-02-23
JP6121369B2 (ja) 2017-04-26
CA3034396A1 (en) 2008-08-07
US20180289786A1 (en) 2018-10-11
US20210252119A1 (en) 2021-08-19
AU2008211227B2 (en) 2014-04-17
EP2125883B9 (en) 2014-04-23
JP2021107443A (ja) 2021-07-29
US20180289784A1 (en) 2018-10-11
US10925939B2 (en) 2021-02-23
CA2915168C (en) 2017-05-23
CA2915168A1 (en) 2008-08-07
US20210236609A1 (en) 2021-08-05
IL267186A (en) 2019-08-29
US20190351036A1 (en) 2019-11-21
US11045528B2 (en) 2021-06-29
US10213496B2 (en) 2019-02-26
US11844826B2 (en) 2023-12-19
US20180289785A1 (en) 2018-10-11
KR101722305B1 (ko) 2017-03-31
IL245478B (en) 2019-07-31
MX347197B (es) 2017-04-18
US20220211827A1 (en) 2022-07-07
EP2423221A1 (en) 2012-02-29
CA2677073A1 (en) 2008-08-07
EP2450371B1 (en) 2015-04-29
US10925940B2 (en) 2021-02-23
EP2423222B9 (en) 2016-09-14
EP2450370A1 (en) 2012-05-09
US11045532B2 (en) 2021-06-29
US10980867B2 (en) 2021-04-20
JP2021073255A (ja) 2021-05-13
JP5643739B2 (ja) 2014-12-17
US20160000892A1 (en) 2016-01-07
HK1197250A1 (en) 2015-01-09
EP2450367A1 (en) 2012-05-09
IL200129A (en) 2016-10-31
CN101687912B (zh) 2014-01-22
EP2423220B1 (en) 2015-04-29
WO2008094538A2 (en) 2008-08-07
JP2024059975A (ja) 2024-05-01
EP2896630B1 (en) 2020-12-23
CA3001783A1 (en) 2008-08-07
EP2125883B2 (en) 2020-11-18
EP2423222B1 (en) 2015-04-29
EP2450372B1 (en) 2015-04-22
US10925941B2 (en) 2021-02-23
EP2125883B1 (en) 2011-09-21
US20190030144A1 (en) 2019-01-31
EP2450366A1 (en) 2012-05-09
JP2017165733A (ja) 2017-09-21
CA3161849A1 (en) 2008-08-07
US20090018067A1 (en) 2009-01-15
EP2423219B1 (en) 2015-04-29
US12016909B2 (en) 2024-06-25
WO2008094538A3 (en) 2009-02-26
EP2423222A1 (en) 2012-02-29
JP2014240404A (ja) 2014-12-25
US20180289788A1 (en) 2018-10-11
EP2450369A1 (en) 2012-05-09
IL200129A0 (en) 2010-04-15
JP6472476B2 (ja) 2019-02-20

Similar Documents

Publication Publication Date Title
JP6472476B2 (ja) 調節性ｔ細胞エピトープ、組成物およびその使用
AU2014201846B2 (en) Regulatory t cell epitopes, compositions and uses thereof
AU2019200571B2 (en) Regulatory T cell epitopes, compositions and uses thereof
HK1242342B (zh) 调节性t细胞表位、组合物及其用途

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110425

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20110425

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20110609

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110622

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110921

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20111013

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20111111

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20141118

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4866467

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees